Patients known to be human immunodeficiency virus (HIV) positive with a baseline cluster of differentiation (CD) count of <  cells/mm^ or have a history of acquired immune deficiency syndrome (AIDS) indicator conditions
STEP I: Human immunodeficiency virus (HIV) infection is not excluded; known HIV positive patients must meet the following criteria:\r\n* Cluster of differentiation (CD) cell count >= /mm^\r\n* No history of acquired immune deficiency syndrome (AIDS)-related illness\r\n* Not currently prescribed zidovudine or stavudine
Patients known to be human immunodeficiency virus (HIV) positive with one or more of the following:\r\n* Baseline cluster of differentiation (CD) count of <  cells/mm^\r\n* History of acquired immune deficiency syndrome (AIDS) indicator conditions\r\n* Anti-retroviral therapy with any potent CYPA inhibitor
Known history of positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome.
Participants with persistently low CD counts less than  and a history of any acquired immune deficiency syndrome (AIDS)-defining infection in the last  months before screening are excluded from the study
Any patient with a history of genetic or acquired immune suppression disease such as human immunodeficiency virus (HIV) is excluded; subjects on immune suppressive therapy for organ transplant are also excluded
Known history of positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome.
Active uncontrolled infection, including known history of human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) or hepatitis B or C
Known infection with human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS) (testing not required).
History or current status of immune system abnormalities such as hyperimmunity (e.g., autoimmune diseases) that needed to be treated by systemic therapy, such as immuno-suppressants and hypoimmunity (e.g., myelodysplatic disorders, marrow failures, acquired immune deficiency syndrome [AIDS], transplant immunosuppression)
Acquired immune deficiency syndrome (AIDS) due to the potential for increased complications from treatment; note, however, that HIV testing is not required
Have known immune system disorders (including acquired immunodeficiency syndrome [AIDS], HIV infection or hepatitis B or C); eligible patients must have a negative HIV test result within  weeks prior to study initiation
History or current status of immune system abnormalities such as hyperimmunity (e.g., autoimmune diseases) that needed to be treated by systemic therapy, such as immuno-suppressants and hypoimmunity (e.g., myelodysplastic disorders, marrow failures, acquired immune deficiency syndrome [AIDS], transplant immunosuppression)
Known to have lymphoma related to HIV or acquired immune deficiency syndrome (AIDS)
Patients with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) and those severely immunocompromised will be excluded; however, no patients will be tested for HIV
Acquired immune defects such as human immunodeficiency virus (HIV) or innate immunodeficiency
Known history of positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome
Known Human Immunodeficiency Virus (HIV) or Acquired Immune Deficiency Syndrome (AIDS)
Has known immunosuppressive disease (e.g. human immunodeficiency virus [HIV], acquired immunodeficiency syndrome [AIDS] or other immune depressing disease); testing is not required, only to be done for a possible diagnosis which is not confirmed
Known significant immunodeficiency due to underlying illness (e.g. HIV/acquired immunodeficiency syndrome [AIDS]) and/or immune-suppressive medication including high-dose corticosteroids (defined as >=  mg/day prednisone or equivalent which is ongoing at the time of enrollment and/or was taken for more than  weeks within the preceding  months of enrollment)
Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) even if fully immunocompetent on antiretroviral therapy (ART)due to the unknown effects of HIV on the immune response to combined nivolumab plus ipilimumab or the unique toxicity spectrum of these drugs in patients with HIV
Known history of human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS)
Active or history of uveal, mucosal, or ocular melanoma. Human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS)-related illness, chronic hepatitis B or C.
History of any chronic Hepatitis, active Hepatitis B or C, human immunodeficiency virus (HIV), or acquired immune deficiency syndrome (AIDS)
Has known immunosuppressive disease (e.g. human immunodeficiency virus [HIV], acquired immune deficiency syndrome [AIDS] or other immune depressing disease); testing is not mandatory
Subjects who require human immunodeficiency virus (HIV) protease inhibitors or those with acquired immune deficiency syndrome (AIDS)-related illness
Known human immunodeficiency virus (HIV) positivity or acquired immune deficiency syndrome (AIDS)-related illness
Immune deficiency: clinically significant primary or acquired immune deficiency (i.e. acquired immunodeficiency syndrome [AIDS] or on immunosuppressive medication after organ transplant)
Known human immunodeficiency virus positive (HIV[+]) or has been diagnosed with acquired immune deficiency syndrome (AIDS)
History or evidence of sarcoma associated with immunodeficiency states (e.g.: hereditary immune deficiency, human immunodeficiency virus (HIV), organ transplant or leukemia)
Because patients with immune deficiency are not expected to respond to this therapy, human immunodeficiency virus (HIV)-positive patients are excluded from the study
Active uncontrolled infection, including known history of acquired immune deficiency syndrome (AIDS) or hepatitis B or C
If there is clinical suspicion of acquired immune deficiency syndrome (AIDS), a human immunodeficiency virus (HIV) test must be done within  days prior to registration; Note: HIV positive patients with a cluster of differentiation (CD)+ T cell count >  per uL of blood and > % of all lymphocytes are eligible for this trial
Patients with immune deficiency have impaired immune responses, therefore, known human immunodeficiency virus (HIV)-positive patients are excluded from the study
Patients with known history of human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS)
Evidence of immune suppression due to: a) known human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS); b) known leukemia or lymphoma; c) those who require high dose steroids (>  mg/day of prednisone or equivalent within  days prior to enrollment) or other immunosuppressive therapies (>  weeks); d) active hepatitis B or C; e) congenital or acquired cellular and/or humoral immune deficiency; f) other signs or symptoms of immune system suppression or concurrent opportunistic infection
Known positive testing for human immunodeficiency virus (HIV)or history of acquired immune deficiency syndrome (AIDS).
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; however, HIV-positive patients without an acquired immune deficiency syndrome (AIDS)-defining diagnosis who are not receiving agents with the potential for pharmacokinetic (PK) interactions with ABT- may be eligible
The first six patients enrolled in the FltL arm of the study cannot be human immunodeficiency virus (HIV)-positive; after the evaluation of safety in the first  patients, HIV-positive patients with adequate immune function as evidenced by stable cluster of differentiation (CD) counts >= /mm^ are allowed to participate if the following criteria are met:\r\n* Maintained on stable antiretroviral therapy with no significant drug interactions, and \r\n* No recent history of acquired immune deficiency syndrome (AIDS) indicator conditions (>  years from enrolling in trial), and \r\n* Physician providing patients care for HIV must also approve of patient entering the study
Patients known to be human immunodeficiency virus (HIV) positive with a baseline cluster of differentiation (CD) count of <  cells/mm^ or have a history of acquired immune deficiency syndrome (AIDS) indicator conditions; patients taking anti-retroviral therapy that may have a potential overlapping toxicity with the study therapy are not eligible
Human immunodeficiency virus (HIV) positive serology or acquired immune deficiency syndrome
A known diagnosis of human immunodeficiency virus (HIV) infection or acquired immune\n             deficiency syndrome (AIDS), acute or chronic hepatitis B or hepatitis C infection, as\n             determined by medical history.
Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) even if fully immunocompetent on ARTdue to the unknown effects of HIV on the immune response to combined nivolumab plus ipilimumab or the unique toxicity spectrum of these drugs in patients with HIV
Human immunodeficiency virus (HIV) infection is not excluded; HIV+ patients must meet the following criteria:\r\n* Cluster of differentiation (CD) cell count >= /mm^\r\n* No history of acquired immune deficiency syndrome (AIDS)-related illness\r\n* Not currently prescribed zidovudine or stavudine
Absence of history of acquired immune deficiency syndrome (AIDS)-related conditions (other than the presenting DLBCL) or post-transplant lymphoproliferative disorder (PTLD) in immunocompromised patients; patients with human immunodeficiency virus (HIV) on antiretroviral therapy other than zidovudine (AZT) and/or stavudine and without prior AIDS defining conditions and adequate CD count (> ) are eligible
HIV positive patients with advanced immune suppression and evidence of HIV resistant to all combinations of antiretroviral therapy considered at high risk of non-lymphoma related death within -months due to other acquired immune deficiency syndrome (AIDS) complications should not be enrolled on the study
Evidence of immune suppression due to: \r\n* Known human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)\r\n* Known leukemia or lymphoma\r\n* Those who require high dose steroids or other immunosuppressive agents\r\n* Known hepatitis B or C infection \r\n* Congenital or acquired cellular and/or humoral immune deficiency\r\n* Other signs or symptoms of immune system suppression
Human immunodeficiency virus (HIV) infection without acquired immune deficiency syndrome (AIDS)-defining criteria are eligible
Clinically significant autoimmune disorders or conditions of immunosuppression; patients with acquired immunodeficiency syndrome (AIDS) or human immunodeficiency virus (HIV)- associated complex or known to be HIV antibody seropositive or known to be recently polymerase chain reaction (PCR)+ for hepatitis B or C are not eligible for this study; the severely depressed or altered immune system found in these patients and the possibility of premature death would compromise study objectives
Patients with human immunodeficiency virus (HIV) who are not receiving cytochrome p inhibitors, and who have a minimum of + CD+ cells/mm^, an undetectable viral load, and no history of acquired immune deficiency syndrome (AIDS) indicator conditions
Known positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome
Known immune deficiency, including human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus positive (HIV)(+) or has been diagnosed with acquired immune deficiency syndrome (AIDS)
Subjects with known infection with human immunodeficiency virus (HIV) or Acquired Immune Deficiency Syndrome (AIDS)
History of genetic or acquired immune suppression disease such as human immunodeficiency virus (HIV); subjects on immune suppressive therapy for organ transplant
Subjects who require human immunodeficiency virus (HIV) protease inhibitors or those with acquired immune deficiency syndrome (AIDS)-related illness
Prior chronic immune suppressive state (acquired immune deficiency syndrome [AIDS], immunosuppressive therapy)
Known chronic infectious disease including, but not limited to, human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS)
History of immune system abnormalities such as hyperimmunity (e.g., autoimmune diseases) and hypoimmunity (e.g., myelodysplastic disorders, marrow failures, acquired immune deficiency syndrome [AIDS], ongoing pregnancy, transplant immunosuppression)
For patients with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), the following must be true:\r\n* The patient is compliant on combination anti-retroviral therapy (CART)\r\n* The patient has cluster of differentiation (CD) count >=  at time of diagnosis
Serious uncontrolled infection; known human immunodeficiency virus (HIV)-seropositivity requiring retroviral therapy, or diagnosis of acquired immune deficiency syndrome (AIDS); diagnosis of chronic hepatitis B or C allowed
Conditions associated with increased susceptibility to infections with microorganisms; such conditions include, but are not limited to, acquired immune deficiency syndrome (AIDS), leukemia and intravenous (IV) drug abuse
Subjects with known infection with human immunodeficiency virus (HIV) or Acquired Immune Deficiency Syndrome (AIDS) (testing not required).
Human immunodeficiency virus (HIV)+/acquired immune deficiency syndrome (AIDS)
. Subjects with known infection with human immunodeficiency virus or Acquired Immune Deficiency Syndrome (testing not required).
Known human immunodeficiency virus (HIV) positivity or acquired immune deficiency syndrome (AIDS)-related illness, active hepatitis B virus, or active hepatitis C virus
Has known human immunodeficiency virus or acquired immune deficiency syndrome, hepatitis B, hepatitis C, connective tissue disease, or other clinical diagnosis, ongoing or intercurrent illness that in the Investigators opinion should preclude the subject from participation;
Patients seropositive for the human immunodeficiency virus (HIV), and/or those who are taking anti-retroviral treatment for HIV/acquired immune deficiency syndrome (AIDS)
Patients with known history of human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS)
Known human immunodeficiency virus (HIV) positive or history of acquired immune deficiency syndrome (AIDS) or AIDS-defining illness
Acquired immuno deficiency syndrome (AIDS-related illnesses) or known human immunodeficiency virus (HIV) disease requiring antiretroviral treatment
Positive test for human immunodeficiency virus (HIV) & or known Acquired immune deficiency syndrome (AIDS)
Presence of human immunodeficiency virus (HIV) infection or acquired immune deficiency syndrome (AIDS)
Co-morbidity with immunosuppressive disease such as acquired immune deficiency syndrome (AIDS)
Known positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome
Positive test result for human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS)
Individuals who are immunosuppressed by virtue of medication or disease, as determined by the examining study physician; this includes acquired immune deficiency syndrome (AIDS) patients and subjects taking oral steroids
History or serologic evidence of chronic viral infection (hepatitis B or C), human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS)
Known history of Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), hepatitis B or C.
Immune compromised individuals (human immunodeficiency virus [HIV], acquired immune deficiency syndrome [AIDS], immuno-suppressive drug therapy)
Known positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome.
Patients with major chronic disease known to adversely affect PA, including human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), congestive heart failure, tuberculosis
